Molecular Medicine

, Volume 14, Issue 1–2, pp 28–35 | Cite as

The Antithrombotic Effect of Angiotensin-(1-7) Involves Mas-Mediated NO Release from Platelets

  • Rodrigo Araújo Fraga-Silva
  • Sergio Veloso Brant Pinheiro
  • Andrey Christian Costa Gonçalves
  • Nathalia Alenina
  • Michael Bader
  • Robson Augusto Souza Santos
Research Article


The antithrombotic effect of angiotensin(Ang)-(1-7) has been reported, but the mechanism of this effect is not known. We investigated the participation of platelets and receptor Mas-related mechanisms in this action. We used Western blotting to test for the presence of Mas protein in rat platelets and used fluorescent-labeled FAM-Ang-(1-7) to determine the specific binding for Ang-(1-7) and its displacement by the receptor Mas antagonist A-779 in rat platelets and in Mas−/− and Mas+/+ mice platelets. To test whether Ang-(1-7) induces NO release from platelets, we used the NO indicator DAF-FM. In addition we examined the role of Mas in the Ang-(1-7) antithrombotic effect on induced thrombi in the vena cava of male Mas/ and Mas+/+ mice. The functional relevance of Mas in hemostasis was evaluated by determining bleeding time in Mas+/+ and Mas/ mice. We observed the presence of Mas protein in platelets, as indicated by Western Blot, and displacement of the binding of fluorescent Ang-(1-7) to rat platelets by A-779. Furthermore, in Mas+/+ mouse platelets we found specific binding for Ang-(1-7), which was absent in Mas/ mouse platelets. Ang-(1-7) released NO from rat and Mas+/+ mouse platelets, and A-779 blocked this effect. The NO release stimulated by Ang-(1-7) was abolished in Mas/ mouse platelets. Ang-(1-7) inhibited thrombus formation in Mas+/+ mice. Strikingly, this effect was abolished in Mas/ mice. Moreover, Mas deficiency resulted in a significant decrease in bleeding time (8.50 ± 1.47 vs. 4.28 ± 0.66 min). This study is the first to show the presence of Mas protein and specific binding for Ang-(1-7) in rat and mouse platelets. Our data also suggest that the Ang-(1-7) antithrombotic effect involves Mas-mediated NO release from platelets. More importantly, we showed that the antithrombotic effect of Ang-(1-7) in vivo is Mas dependent and that Mas is functionally important in hemostasis.



This work was supported in part by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG), and Programa de Apoio a Núcleos de Excelência (FAPEMIG/CNPq-PRONEX). RA Fraga-Silva is the recipient of support from Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES).


  1. 1.
    Lip GY, Edmunds E, Beevers DG. Should patients with hypertension receive antithrombotic therapy? J. Intern. Med. 2001;249(3):205–14.CrossRefPubMedGoogle Scholar
  2. 2.
    Willoughby S, Holmes A, Loscalzo J. Platelets and cardiovascular disease. Eur. J. Cardiovasc. Nurs. 2002;1:273–88.CrossRefPubMedGoogle Scholar
  3. 3.
    Packham MA. Role of platelets in thrombosis and hemostasis. Can. J. Physiol. Pharmacol. 1994;72:278–84.CrossRefPubMedGoogle Scholar
  4. 4.
    Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ. Res. 2001;88:756–62.CrossRefPubMedGoogle Scholar
  5. 5.
    Griendling KK, Murphy TJ, Alexander RW. Molecular biology of the renin-angiotensin system. Circulation 1993;87:1816–28.CrossRefPubMedGoogle Scholar
  6. 6.
    Kucharewicz I, Pawlak R, Matys T, et al. Angiotensin-(1-7): an active member of the renin-angiotensin system. J. Physiol. Pharmacol. 2002;53(4 Pt 1):533–40.PubMedGoogle Scholar
  7. 7.
    Nishimura H, Tsuji H, Masuda H, et al. Angiotensin II increases plasminogen activator inhibitor-1 and tissue factor mRNA expression without changing that of tissue type plasminogen activator or tissue factor pathway inhibitor in cultured rat aortic endothelial cells. Thromb. Haemost. 1997;77:1189–95.CrossRefPubMedGoogle Scholar
  8. 8.
    van Leeuwen RT, Kol A, Andreotti F, et al. Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation 1994;90:362–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Moore TJ, Williams GH. Angiotensin II receptors on human platelets. Circ. Res. 1982;51:314–20.CrossRefPubMedGoogle Scholar
  10. 10.
    Jagroop IA, Mikhailidis DP. Angiotensin II can induce and potentiate shape change in human platelets: effect of losartan. J. Hum. Hypertens. 2000;14:581–5.CrossRefPubMedGoogle Scholar
  11. 11.
    Kalinowski L, Matys T, Chabielska E, et al. Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension 2002;40:521–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Ferrario CM, Chappell MC, Tallant EA, et al. Counterregulatory actions of angiotensin-(1-7). Hypertension 1997;30(3 Pt 2):535–41.CrossRefPubMedGoogle Scholar
  13. 13.
    Santos RA, Simoes e Silva AC, Maric C, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl. Acad. Sci. USA. 2003;100:8258–63.CrossRefPubMedGoogle Scholar
  14. 14.
    Kucharewicz I, Pawlak R, Matys T, et al. Antithrombotic effect of captopril and losartan is mediated by angiotensin-(1-7). Hypertension 2002;40:774–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Kucharewicz I, Chabielska E, Pawlak D, et al. The antithrombotic effect of angiotensin-(1-7) closely resembles that of losartan. J. Renin Angiotensin Aldosterone Syst. 2000;1:268–72.CrossRefPubMedGoogle Scholar
  16. 16.
    Heitsch H, Brovkovych S, Malinski T, et al. Angiotensin-(1-7)-stimulated nitric oxide and superoxide release from endothelial cells. Hypertension 2001;37:72–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Pinheiro SV, Simoes e Silva AC, Sampaio WO, et al. Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor Mas agonist in the mouse kidney. Hypertension 2004;44:490–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Sampaio WO, Souza dos Santos RA, Faria-Silva R, et al. Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension 2007;49:185–92.CrossRefPubMedGoogle Scholar
  19. 19.
    Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976;72:248–54.CrossRefGoogle Scholar
  20. 20.
    Jantzen HM, Milstone DS, Gousset L, et al. Impaired activation of murine platelets lacking G alpha(i2). J. Clin. Invest. 2001;108:477–83.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Kurz KD, Main BW, Sandusky GE. Rat model of arterial thrombosis induced by ferric chloride. Thromb. Res. 1990;60:269–80.CrossRefPubMedGoogle Scholar
  22. 22.
    Holland JM. Serotonin deficiency and prolonged bleeding in beige mice. Proc. Soc. Exp. Biol. Med. 1976;151:32–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Rajendran S, Chirkov YY, Campbell DJ, et al. Angiotensin-(1-7) enhances anti-aggregatory effects of the nitric oxide donor sodium nitroprusside. J. Cardiovasc. Pharmacol. Oct 2005;46(4):459–63.CrossRefPubMedGoogle Scholar
  24. 24.
    Randriamboavonjy V, Fleming I. Endothelial nitric oxide synthase (eNOS) in platelets: how is it regulated and what is it doing there? Pharmacol. Rep. 2005;57Suppl:59–65.PubMedGoogle Scholar
  25. 25.
    Balcerczyk A, Soszynski M, Bartosz G. On the specificity of 4-amino-5-methylamino-2′,7′-difluorofluorescein as a probe for nitric oxide. Free Radic. Biol. Med. 2005;39(3):327–35.CrossRefPubMedGoogle Scholar
  26. 26.
    Santos RA, Campagnole-Santos MJ, Andrade SP. Angiotensin-(1-7): an update. Regul. Pept. 2000;91:45–62.CrossRefPubMedGoogle Scholar

Copyright information

© Feinstein Institute for Medical Research 2008

Authors and Affiliations

  • Rodrigo Araújo Fraga-Silva
    • 1
  • Sergio Veloso Brant Pinheiro
    • 1
  • Andrey Christian Costa Gonçalves
    • 2
  • Nathalia Alenina
    • 2
  • Michael Bader
    • 2
  • Robson Augusto Souza Santos
    • 1
    • 3
  1. 1.Department of PhysiologyFederal University of Minas GeraisBelo Horizonte, Minas GeraisBrasil
  2. 2.Max-Delbrück Center for Molecular MedicineBerlinGermany
  3. 3.Robson Augusto Souza dos Santos, Departamento de Fisiologia e Biofísica6627-ICB-UFMGBelo Horizonte, MGBrasil

Personalised recommendations